Home Use Study of Targeted Mechanical Stimulation for Tremor Relief

NCT ID: NCT07078422

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects will receive prototype devices to be used for participation. The study comprises three phases:

1. Alpha phase: Two remote study visits and an in-home period to gather device usability data on the alpha system. The at home period for this phase will be 2 weeks. This phase will be used to confirm that the device and labeling are suitable for in-home use.
2. Beta Phase B1: Beta Phase B1 will be conducted using the beta devices for two in-person or remote, 60 to 90-minute, visits. This phase will be used to assess design changes between alpha and beta versions.
3. Beta Phase B2: Seven remote visits and in-home usage to gather usability and efficacy data on the beta system in-home. Beta Phase B2 will be conducted using the beta devices for 12 weeks. This phase will be used to assess design changes between alpha and beta versions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Tremor Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The study design is modeled after a typical movement assessment, relevant to the diagnosis, and modified to apply the treatment. Participants will perform movements typical of the motor assessments both before and during treatment. The intent of the study is to confirm the device design and usability in the subject's home environment. The study will also measure change in treatment effect after long periods of regular use.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Oder of assessment begins with TETRAS and ends with ADLs

Group Type EXPERIMENTAL

Encora Pulse

Intervention Type DEVICE

The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.

This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.

B

Order of assessment begins with ADLs and ends with TETRAs

Group Type EXPERIMENTAL

Encora Pulse

Intervention Type DEVICE

The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.

This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.

C

Order of assessment begins with TETRAS and ends with ADLs, but both are administered backwards

Group Type EXPERIMENTAL

Encora Pulse

Intervention Type DEVICE

The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.

This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.

D

Order of assessment begins with ADLs and ends with TETRAs, but both are administered backwards

Group Type EXPERIMENTAL

Encora Pulse

Intervention Type DEVICE

The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.

This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Encora Pulse

The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.

This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older, able to comply with all study procedures and capable of providing informed consent.
* Mentally competent to understand and able to perform written, informed consent to participate in the study
* A diagnosis of either ET or PD as determined by clinical history
* Moderate to severe upper limb tremor


* Age 18 years or older, able to comply with all study procedures and capable of providing informed consent
* Mentally competent to understand and able to perform written, informed consent to participate in the study
* For ET subjects, a diagnosis of essential tremor defined as definite or probable ET based on TRIG criteria
* For PD subjects, a diagnosis of Parkinson's disease by a Movement Disorder Specialist
* For ET subjects, at least one hand exhibiting tremor \> 2 as assessed by the Essential Tremor Rating Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit
* For PD subjects, a score \> 2 on at least one of MDS-UPDRS items 3.15, 3.16 or 3.17 At the Screening Visit, a score of \> 3 on one of the following subject-assessed items of the Bain \& Findley Activities of Daily Living Scale (BF-ADL): Use a spoon to drink soup, Hold a cup of tea, Do up buttons, Do up a zipper, Write a letter
* Stable medications for at least 30 days prior to enrollment and the ability to maintain tremor medications throughout the duration of study participation
* For PD subjects, able to participate in visits in a practically defined OFF state (withdrawal from all tremor medication for 12 hours prior to study visits)
* A wrist circumference of 6.0 - 8.1 inches

Exclusion Criteria

* Pregnant women
* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
* History of psoriasis, eczema or atopic dermatitis at the stimulation site
* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and diabetic neuropathy
* Participant unable to communicate with sponsor/investigator and staff
* Any other medical conditions or physical or mental impairments that in the sponsor/investigator's opinion would render the subject unsuitable as a candidate for the study.


* Pregnant women
* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
* History of psoriasis, eczema or atopic dermatitis at the stimulation site
* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and -diabetic neuropathy
* Participant unable to communicate with sponsor/investigator and staff
* Any other medical conditions or physical or mental impairments that in the sponsor/investigator's opinion would render the subject unsuitable as a candidate for the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Encora, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ann Marie Murray, MD

Role: PRINCIPAL_INVESTIGATOR

WVU Comprehensive Movement Disorder Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Encora Therapeutics

Cambridge, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Allison Davanzo

Role: CONTACT

855-937-5302

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Allison Davanzo

Role: primary

855-937-5302

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20232333

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.